2023-04-24 22:54:59
By Le Figaro with AFP
Published update
This content is not accessible.
The American pharmaceutical giant Johnson & Johnson (J&J) announced on Monday April 24 that it wanted to launch its branch of hygiene products, beauty products and non-prescription drugs on Wall Street at a price valuing it between 37 and 43 billion dollars.
The company announced at the end of 2021 that it wanted to separate this entity, which includes Tylenol headache tablets, Band-Aid plasters and Neutrogena creams, from the rest of its operations. She said on Monday that she wanted to put on the market, at an undetermined date, 151.2 million shares of the new company, called Kenvue, at a price of between 20 and 23 dollars per unit. This would allow the company to raise between 3 and 3.5 billion dollars on this occasion.
This content is not accessible.
This operation is announced at a time when, after a complicated year for IPOs due to rising interest rates, falling markets and economic uncertainties, arrivals on Wall Street are starting up again timidly. Kenvue would trade on the New York Stock Exchange under the symbol KVUE. After its completion, Johnson & Johnson would still own approximately 92% of Kenvue, 91% if an over-allotment option is used.
1682397612
#Johnson #Johnson #list #consumer #products #billion